Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC): Efficacy and Toxicity Evaluation
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 31 May 2023 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.
- 31 May 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
- 31 May 2023 Status changed from recruiting to active, no longer recruiting.